The value of integrating national longitudinal shopping data into respiratory disease forecasting models.
Latigo secures $150m for non-opioid pain treatment development
The company has recently shared Phase I outcomes for an orally administered candidate for non-opioid pain relief. Credit: meeboonstudio/Shutterstock. Latigo Biotherapeutics has secured $150m in